Clinical Trial Results

Showing: All studies [change]
Condition: Breast Cancer Location: Hot Springs, Arkansas 25 trials found
New Search
Filter
Trial Phase
Study Type
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NAINTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
PHASE2, PHASE3INTERVENTIONAL Hot Springs, Arkansas +4 more
RECRUITING
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
PHASE3INTERVENTIONAL Hot Springs, Arkansas +4 more
RECRUITING
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
PHASE1INTERVENTIONAL Hot Springs, Arkansas +4 more
RECRUITING
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
PHASE4INTERVENTIONAL Tucson, Arizona +4 more
RECRUITING
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Caris Biorepository Research Protocol
N/AOBSERVATIONAL Mobile, Alabama +4 more
RECRUITING
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
PHASE1INTERVENTIONAL Little Rock, Arkansas +4 more
RECRUITING
E-Mindfulness Approaches for Living After Breast Cancer
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
PHASE3INTERVENTIONAL Jonesboro, Arkansas +4 more
RECRUITING
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
PHASE3INTERVENTIONAL Phoenix, Arizona +4 more
RECRUITING
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
PHASE2INTERVENTIONAL Little Rock, Arkansas +4 more
RECRUITING
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
PHASE2INTERVENTIONAL Little Rock, Arkansas
RECRUITING
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
N/AOBSERVATIONAL Birmingham, Alabama +4 more
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
N/AOBSERVATIONAL Anchorage, Alaska +4 more
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Filter Trials
Trial Phase
Study Type